Dr Khan CV Final (1)-converted.pdf -

Please enable JavaScript to view the full PDF

MUHAMMAD A. KHAN, MD. [email protected] Orlando, Florida (321)229-5300 WORK EXPERIENCE: ⬧ Cano-Health, FL (June 2019- Present) ⬧ Attending Physician & Medical Director, supervised 12 providers at 4 locations in Central FL. ⬧ Conducted weekly 8-hour medical director management responsibilities. ⬧ Systematic reviews of clinic billings and medical records for proper documentations per ACHA guidelines ⬧ Collaborated with providers and staff to develop service-based model of patient care, to ensure that clinics and facilities are operating efficiently and within the defined legal parameters. Time was spent on Quality Improvements, Utilization Management, Risk Management and updates on Managed care guidelines and data analysis. ● Central Florida Internists, FL (Feb 2001 – June 2019) ⬧ Physician and Chief Executive Officer Managed four full-time clinics, supervision of 8 physicians, 7 Allied health providers ⬧ Actively represented the practice on multiple service lines and health system quality and utilization review, at least 1 hour a day. ⬧ At least 4 hours a week time spent to optimize policy and procedure changes within the service line, reviewing, collecting feedback, and sharing recommendation. ⬧ Monthly 4 hour providers meeting for Quality, Utilization, Risk and Case management ⬧ • Physicians Associates of Florida (Aug 1997- January 2001) Attending physician and Partner, a leading role in establishing hospitalist program in Greater Orlando area for the organization. ● Shepherd's Hope, Central Florida. (1997-Present) Position: Volunteer Physician, Shephard’s hope provides free primary care and specialty care medical services, education and wellness programs to uninsured and underinsured men, women, and children in Central Florida. Management Experience: • Founder, Administrator, and CEO of Central Florida Internists • Medical Director Cano Health • Medical Directors for eight (8) Long Term care facilities in Central Florida, providing clinical & administrative services, chart review, physicians, and medical staff communications. • Secretary, Osceola Hospital Kissimmee, Florida • Board member Osceola Hospital Kissimmee Florida • Credentialing committee member Osceola Hospital Kissimmee • Quality assurance/Peer review committee member • Member Senior Resource Alliance of Central Florida • Medical Director Home Health Care • ACHA Certified Medical Reviewer • Pharmacy Committee Member St cloud Regional Medical Center • Medical Advisor for SilverVue/Mingle Health, A MACRA solution platform. Hospital Affiliations and Privileges • Advent Health Hospital system • Orlando Health Hospital system • Osceola Regional Hospital System • St Cloud Regional Hospital • Health Central Hospital EDUCATION: ● June 1986 - April 1992: Dow Medical College, Karachi, Pakistan Bachelor of Medicine, Bachelor of Surgery (MB, BS, MD Equivalent) Internship & Residency: ● April 1992 - April 1993: Civil Hospital Karachi, Karachi, Pakistan - Medicine Residency ● April 1993 - May 1994: On Vacation ● June 1994 - June 1997: Wayne State University, Detroit, Michigan - Internal Medicine LICENSURES AND CERTIFICATION: • Florida State License (1997-Present) • Virginia State license (2021-Present) ● American Boards of Internal Medicine (1997) ● ECFMG Basic Science (1993) ● ECFMG Clinical Science HONORS AND AWARDS: ● Research Competition Award, Wayne State University (1995) ● Gold Medal for Academic Excellence, Dow Medical College (1992) ● Ranked 2nd in Medical School in a class of 450 CLINICAL RESEARCH EXPERIENCE: • Clinical Research of Hollywood (2021- present) DBA Cano Research ● ONCOVA. Clinical Research, Inc. (September 2012- June 2019) Position: Principal Investigator Kissimmee, FL ● Tri-Quest Clinical Research, Inc. (June 2009- August 2012) Position: Clinical Investigator ● DUROOI-301: A Phase 3 Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections. ● Protocol DAS181-02-04: A Phase IIB Randomized, Double-Blind, Placebo-Controlled study on Safety and Therapeutic Efficacy of DAS 181 in adults with naturally acquired Influenza. ● MB102077: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an additional Antihypertensive medication. ● HZC113782: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25cg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease. ● A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM -101 Compared to Oral Levofloxacin in the Treatment of Patients with Community-Acquired Bacterial Pneumonia ● A Phase 2 exploratory study of objective endpoints in subjects with acute bacterial skin and skin structure infections treated with delafloxacin, vancomycin or linezolid ● 32729463CAP2001: A Randomized, Controlled, Double-Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared with Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community Acquired Bacterial Pneumonia (CABP) With a PORT Score of II or Greater. ● A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients with Irritable Bowel Syndrome with Diarrhea. ● A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in patients with Clostridium Difficile Infection. ● A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease. ● SYR-322_ 402: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome. ● A Randomized, Controlled, Double-Blind, Double-Dummy, Multicenter Phase 2 Study of the Safety/Tolerability and Efficacy of XXXXX Compared with Linezolid (Zyvox) for the Treatment of Complicated Skin and Skin Structure Infection. ● A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared Rosuvastatin Monotherapy in Dyslipidemic Subjects with Stage 3 Chronic Kidney Disease. ● A phase II, Randomized, Double-Blind, Placebo controlled, Multicenter Study Evaluating the Efficacy and Safety of Two Doses of favipiravir in older Adult Patients with Uncomplicated Influenza. ● A Double-Blind, Randomized, Comparator-Controlled Study to Assess the Safety, Efficacy, and Pharmacodynamics of Two Durations of ACHN-490 Injection Administered Intravenously (IV) in Patients with Complicated Urinary Tract Infections (cUTI) or Acute Pyelonephritis (AP). ● Comparison of Sulfahyrated Ace Inhibitors in hypertensive and diabetic patients as anti- ischemic agents. ● INVEST, International Verapamil SR-Trandolapril Study; site investigator. ● Comparison of Meloxicam Cox -2 Inhibitor with traditional non-steroid anti- inflammatory drugs in osteoarthritis; site investigator. ● Prospective, Randomized, Double-Blind Study Comparing Faropenem Daloxate 300mg PO BID for five days with Trimethoprim/Sulfamethoxazole 160/800 mg PO BID for five days in the treatment of patients with acute, uncomplicated Urinary Tract Infections. ● Fenofibrate and Cervastatin Trial Optimizing Response, A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study of the Safety and Effectiveness of Cerivastatin in Combination with Fenofibrate Compared to Cerivastin Alone, Fenofibrate Alone, and Placebo in a population of Type 2 Diabetic Men and Women. ● A 10-12 Week Multicenter, Randomized, Double-Blind, Parallel Group to Study to Evaluate the Efficacy and Safety of the Combination of Valsartan (320 mg) and Simvastatin (80 mg) Compared to Valsartan (320 mb) and Simvastatin (80 mg) Monotherapies in Essential Hypertension and Hypercholesterolemia. ● CLINICAL RESEARCH COURSE CERTIFICATION: ● “Protecting Human Research Participants” - Sponsored by the National Institute of Health (NIH) • Good Clinical practice Certification ● CITI Collaborative Institutional Training Initiative (Sponsored by Quorum) - Biomedical Research - CITI Good Clinical Practice (GCP) - CITI Health Information Primary and Security (HIPS) for All Researchers ● Certified Electronic Data Capture (EDC) - Perceptive Informatics, Data Labs - Oracle and Medidata ABSTRACTS AND ORAL PRESENTATION: ● A rare and Interesting Case of Scleroderma Adult rum of Buscheke. ● Actinomyces infection of Esophageal Ulcer in HIV Patients, a Rare Entity. ● An Interesting Case of Toxic Megacolon Secondary to Pseudomembranous Colitis. ● A Rare and Interesting Case of Salmonella Leg Abscess in Sickle Cell Patients. ● A Case of Streptococcal Miller Meningitis in a Patient with Congenital Heart Disease. ● Unusual Presentation of Neurosyphilis in HIV Patients. Hobbies and Interests: I love spending time in my garden, have tropical garden with more than 130 fruit trees in Florida, along with Stone fruit collection in Virginia. I enjoy travelling, music, movies and reading history books. __________________________ Muhammad A. Khan, MD